glp 1 gip gcg receptor agonist GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Targeting GLP-1, GIP & GCG

2013M540426)

Agua, L-Carnitina, Inulina, Colina, Regulador de la Acidez (cido Fosfrico), Aromatizantes Naturales, Sal, Edulcorante (Sucralosa), Conservantes (Sorbato de Potasio, Benzoato de Sodio), Vitamina B5, Vitamina B6, Vitamina B12.

10.1002/dc.24895 50

Some drugs may interact with this medication, affecting how it works or increasing the risk of side effects

When intra-portal insulin levels are increased (e.g., obesity, Cushings syndrome, or due to treatment with glucocorticoids and glucagon-like peptide 1 receptor agonists) or decreased (e.g., malnutrition, anorexia nervosa and type 1 diabetes mellitus), these changes secondarily alter hepatic GH sensitivity resulting in a secondary association with discordant GH and IGF-I levels (e.g., high GH/low IGF-I levels or low GH/high IGF-I levels, respectively)

Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinsons disease with cognitive impairment in a Chinese population